Ganciclovir, sold under the brand name Cytovene among others, is an antiviral medication used to treat cytomegalovirus (CMV) infections. Ganciclovir was patented in 1980 and approved for medical use in 1988. Ganciclovir is normally connected with a scope of genuine hematological unfriendly impacts. Regular unfavorable medication responses (≥1% of patients) include: granulocytopenia, neutropenia, sickliness, thrombocytopenia, fever, sickness, retching, dyspepsia, loose bowels, stomach torment, fart, anorexia, raised liver compounds, migraine, disarray, mind flight, seizures, agony and phlebitis at infusion site (because of high pH), perspiring, rash, tingle, expanded serum creatinine and blood urea fixations. Global Ganciclovir Market was valued at just under USD 77.5 million in 2020 and is expected to reach over USD 115 million in 2027, growing at a CAGR of over 4.75% during the forecast period.
By type, global Ganciclovir market is segmented into Injection and Oral. In 2019, global Ganciclovir market was dominated by Injection segment with over 50% share in total revenue generation. It is also expected to be one of the fastest growing segments over the forecast period and maintain its dominance.
Download FREE Sample PDF of Global Ganciclovir Market: https://www.eonmarketresearch.com/sample/76632
Global Ganciclovir market is segmented on the basis of applications such as AIDS, Tube transplant, Malignant neoplasms and CMV Infection. AIDS segment dominated the global Ganciclovir market with over 40% share in 2019. Despite of many awareness programs, AIDS patients are still growing at slow but steady pace. This in turn mobilizing the demand for Ganciclovir. Ganciclovir is part of cytomegalovirus treatment. The expanding number of organ transfers, Prevalence of suggestive CMV diseases, Increasing public mindfulness identified with herpes infection contaminations, Pipeline drugs by key market players for the treatment of CMV disease are likely to boost the demand for Ganciclovir.
Asia Pacific dominated the global Ganciclovir market in 2019 with over 45% share in total revenue generated by this industry. Asia Pacific is closely followed by the Africa. High prevalence of AIDS in Asia and Africa is majorly driving the demand for Ganciclovir in the region.
Major players in global Ganciclovir market include but not limited to Roche, Bausch & Lomb, Fresenius Kabi, Luitpold, Huatai Pharmaceutical, Wuhan Hualong Bio-pharmaceutical, Luoxin, HUBEI KEYI, Tungshun Group and Tiantianming. The global Ganciclovir market is highly concentrated with top six players accounting for just over 45% share in the global market.
Buy This Premium Report: https://www.eonmarketresearch.com/buy/76632
Ganciclovir Market by Type, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
Ganciclovir Market by Application, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
- Tube transplant
- Malignant neoplasms
- CMV Infection
Do Inquiry Before Purchasing Report Here and Ask For Discount: https://www.eonmarketresearch.com/enquiry/76632
Ganciclovir Market by Region, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
- United States
- South Korea
- Southeast Asia
Middle East and Africa
- Saudi Arabia
- South Africa
Ganciclovir Market by Company, 2018 – 2019 Volume (Tons) and Revenue (USD Million)
- Bausch & Lomb
- Fresenius Kabi
- Huatai Pharmaceutical
- Wuhan Hualong Bio-pharmaceutical
- HUBEI KEYI
- Tungshun Group
Explore Related Reports:
- Global Kifunensine Market
- Global Trazodone Hydrochloride (API) Market
- Global Solid Organ Transplant Immunosuppressant Market
- Global Primary Hyperoxaluria Drug Market
- Global Cerebroprotein Hydrolysate Market
- Global Caries Detection Devices Market
Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.
Eon Market Research
Phone: +1 703 879 7090